Aviceda Therapeutics
Harnessing the natural immune system to modulate inflammation with highly selective ligands targeting specific immune cells and diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
* | $208m | Series C | |
| Total Funding | 000k | ||
Related Content
Aviceda Therapeutics is a biotechnology company focused on developing innovative treatments for inflammatory diseases by leveraging the natural immune system. The company targets specific immune cells using highly selective ligands designed for maximum specificity and efficacy. Aviceda operates in the biopharmaceutical market, serving patients with life-threatening inflammatory conditions. Its business model revolves around the discovery and development of novel drugs, utilizing proprietary high-throughput screening libraries to create synthetic ligands with high specificity and affinity to Siglecs, a family of receptors on immune cells. Aviceda generates revenue through the development and commercialization of these transformative medicines. The company primarily serves the healthcare sector, including patients, healthcare providers, and research institutions.
Keywords: biotechnology, inflammation, immune system, ligands, Siglecs, drug development, biopharmaceutical, healthcare, synthetic ligands, immune modulation.